# A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct04586426/  
OnCo record `nct04586426` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Talquetamab, Teclistamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04586426 by Janssen Research & Development, LLC, with 228 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-03-18. Interventions recorded: Talquetamab, Teclistamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04586426
- Phase: 1/2
- Setting: A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT04586426: https://clinicaltrials.gov/study/NCT04586426

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Talquetamab](https://onco.cc/drugs/talquetamab/), [Teclistamab](https://onco.cc/drugs/teclistamab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct04586426.json